Skip Navigation

Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections

  1. M. Hong Nguyen1,2,3
  1. 1Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
  2. 2Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  3. 3XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  4. 4Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh Pennsylvania
  5. 5VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
  6. 6Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey
  1. Corresponding Author: Cornelius J. Clancy, MD, Associate Professor of Medicine, University of Pittsburgh, 3550 Terrace Street, S867 Scaife Hall, Pittsburgh, PA 15261, Ph: (412) 647 – 0996, Fax: (412) 648 – 8455, E-mail: cjc76{at}
  1. Noted as contributing equally


Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30-days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90-days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.


Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.